Korea S.E.
06:00:00 2024-04-29 pm EDT
5-day change
1st Jan Change
1,718
KRW
+1.72%
+5.08%
-21.01%
2023
NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.
CI
2023
NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.
CI
SAMSUNG PHARM. Co., LTD. announced that it expects to receive KRW 9.999996279 billion in funding
SAMSUNG PHARM. Co., LTD. (KOSE:A001360) announced a private placement of 2,555,583 common shares at an issue price of KRW 3,913 per share for gross proceeds of KRW 9,999,996,279 on February 21, 2020. The company will issue shares through third-party allotment method. The transaction has been approved by the board of directors of the company.
NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.
23-08-06
CI
NEXTURNBIOSCIENCE Co., Ltd. announced that it expects to receive KRW 9 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd.
23-06-12
CI
Gemvaxzio Co., Ltd. announced that it has received KRW 7.3 billion in funding from SAMSUNG PHARM. Co., LTD.
21-12-08
CI
SAMSUNG PHARM. Co., LTD. Present Pancreatic Cancer Immunotherapeutic Drug, RIAVAX™, Phase III results at ASCO 2021
21-06-05
CI
An unknown buyer agreed to acquire 38.7% stake in Korea Stem Cell Bank Co., Ltd. from SAMSUNG PHARM. Co., LTD. for KRW 9.9 billion.
20-12-29
CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 9.999996279 billion in funding
20-03-01
CI
SAMSUNG PHARM. Co., LTD. announced that it expects to receive KRW 9.999996279 billion in funding
20-02-20
CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 21.7 billion in funding from Kiwoom Investment Co., Ltd., Sangsangin Plus Savings Bank Co.,Ltd.
20-02-13
CI
SAMSUNG PHARM. Co., LTD. completed the acquisition of an unknown minority stake in True Life Insurance Bank for KRW 12.5 billion.
19-04-22
CI
SAMSUNG PHARM. Co., LTD. acquired 3.1% stake in Enerzent Co., Ltd. for KRW 3 billion.
19-01-17
CI
SAMSUNG PHARM. Co., LTD. acquired 0.16% stake in GemVax Technology Co., Ltd. from Samsung Medicos Co., Ltd. for approximately KRW 220 million.
17-11-05
CI
Korea Stem Cell Bank Co., Ltd. agreed to acquire Samsung Medicos Co., Ltd. from SAMSUNG PHARM. Co., LTD. for KRW 16.3 billion.
17-10-30
CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 1.5 billion in funding from J & J Investment Co Ltd and other investor
17-05-18
CI
SAMSUNG PHARM. Co., LTD. announced that it has received KRW 10.2 billion in funding from a group of investors
17-02-05
CI
Samsung Pharmaceutical Co., Ltd. announced that it has received KRW 5.65 billion in funding
16-10-23
CI
Samsung Pharmaceutical Corporation(KOSE:A001360) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index
15-12-01
CI
Samsung Pharmaceutical Co., Ltd. announced that it has received KRW 14.5 billion in funding from a group of investors.
15-10-22
CI
Samsung Pharmaceutical Co., Ltd. announced that it expects to receive KRW 14.5 billion in funding from a group of investors.
15-10-18
CI
Samsung Pharmaceutical Co., Ltd. completed the sale of 17.13% stake in Medizen Humancare Co.,Ltd.
15-10-04
CI
Samsung Pharmaceutical Corporation(KOSE:A001360) added to S&P Global BMI Index
15-09-21
CI
Samsung Pharmaceutical Co., Ltd. agreed to sell 17.13% stake in Medizen Humancare Co.,Ltd. for KRW 2 billion.
15-08-31
CI
Samsung Pharmaceutical Corporation(KOSE:A001360) added to Russell Global Index
15-06-29
CI
Samsung Pharmaceutical Co., Ltd. announced that it has received KRW 15.1 billion in funding from GemVax & Kael Co., Ltd. and other investors.
15-04-02
CI
Samsung Pharmaceutical Co., Ltd. announced that it expects to receive KRW 15.1 billion in funding from GemVax & Kael Co., Ltd., T.S. Investment Corporation, OD Tech Co., Ltd., Lake Investment Advisors, and other investors.
15-03-31
CI
Samsung Pharmaceutical Co., Ltd. acquired Shinhwa IM Co., Ltd. for KRW 3.7 billion.
15-02-12
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SAMSUNG PHARM. Co., LTD., formerly SAMSUNG PHARMACEUTICAL.CO.,Ltd., is a Korea-based company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. The Pharmaceutical and Quasi-drug Sale Business segment manufactures and sells prescription medicines, general pharmaceuticals and quasi-medicines. This segment's products include anticancer immunotherapy agents, antipyretic analgestic and anti-inflammatory agents, hypotensive agents, antiarteriosclerotic agents, anti-spastics, enzyme agents, ostepoposis agents, antibiotics, medicines for digestive system, medicines for liver disorder, medicines for circulation system and vitamin supplements, among others. The Health Food Manufacturing and Sale segment manufactures and sells nutrition and invigoration products.
More about the company
1st Jan change
Capi.
-21.01% 117M +19.27% 43.18B +24.05% 23.23B +15.11% 14.6B +38.36% 11.5B -7.63% 6.79B -0.05% 6.79B -8.87% 5.73B +10.21% 5.31B -2.27% 4.81B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SAMSUNG PHARM. CO., LTD. 
